Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study

作者：Lin Wu, Junling Li, Chong‐Rui Xu, Bivas Biswas, Somnath Roy, Kejing Tang, Huijuan Wang, Ziling Liu, Ullas Batra, Gwo Fuang Ho, J Hooi, You Lü, Mingfang Zhao, Lye Mun Tho, Jun Li Zhao, Shan He, Joan Huang, Hui Zhang, Chew Hooi Wong, Yi-Long Lung Cancer Wu · 发表于：Lung Cancer · 年份：2025 · DOI：10.1016/j.lungcan.2025.108856 · 被引用次数：2 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Lung Cancer Diagnosis and Treatment

BACKGROUND: Dacomitinib, a second-generation, irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), showed statistically significant progression-free survival improvement over gefitinib in patients with treatment-naive EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in the phase 3 ARCHER 1050 study (NCT01774721). We report results from the final analysis of ARIA (NCT04609319), a noninterventional study of dacomitinib's real-world utilization and associated clinical outcomes in Asian patients with EGFR mutation-positive advanced NSCLC. METHODS: This longitudinal, multicenter cohort study collected prospective and retrospective data from patients with EGFR mutation-positive locally advanced or metastatic NSCLC who were treated with first-line dacomitinib. Study objectives were to describe clinical and disease characteristics, therapeutic patterns of dacomitinib use, and clinical outcomes. RESULTS: 299 patients located in China (n = 261), India (n = 24), and Malaysia (n = 14) were enrolled and included in the analysis. Starting dose was 30 mg once daily in 159 (53.2 %) patients, 45 mg once daily in 138 (46.2 %), and other doses in 2 (0.7 %). As of May 28, 2024, 95 patients (31.8 %) had dose reductions, 47 (15.7 %) had dose increases, 41 (13.7 %) had dose interruptions, and 223 (74.6 %) had permanently discontinued dacomitinib. Median duration of treatment was 17.2 months (IQR, 19.2). Median time to treatment failure was 17.0 months...